How targeting cellular recycling centers is revolutionizing cancer treatment and overcoming drug resistance
Deep within every cell in our body lies a remarkable molecular machine—the proteasome. Often described as the cell's recycling center, this barrel-shaped complex performs the essential task of breaking down damaged or unwanted proteins into smaller fragments that can be reused. While this process is crucial for healthy cellular function, cancer cells have learned to hijack it for their own survival.
This article explores how scientists are turning this fundamental cellular structure into a powerful weapon in the fight against cancer, examining both current applications and future possibilities in proteasome-targeted therapies.
Proteasomes break down >80% of cellular proteins
Multiple FDA-approved proteasome inhibitors
Effective against drug-resistant cancers
The proteasome is not a single entity but rather a sophisticated multi-subunit complex. Its core structure, known as the 20S proteasome, forms a hollow, barrel-shaped chamber where protein degradation occurs. This core is capped at one or both ends by a 19S regulatory particle that recognizes and prepares proteins for destruction. Together, they form the 26S proteasome. In some cases, two regulatory particles can attach to a single core, creating a 30S proteasome—a larger complex with potentially different functional properties 2 .
Think of the 20S core as the recycling plant's main processing facility, while the 19S regulatory particles act as the receiving department that identifies, inspects, and prepares incoming materials for processing. Just as a recycling center might have different configurations to handle different types of materials, cells can assemble different types of proteasomes—such as immunoproteasomes—that are particularly efficient at generating protein fragments for immune recognition 6 .
Proteins destined for destruction are first tagged with a small protein called ubiquitin through a sophisticated three-enzyme cascade (E1, E2, and E3 enzymes). This ubiquitin tagging serves as a molecular "kiss of death," marking the protein for recognition by the proteasome's regulatory particles. The E3 ubiquitin ligases are particularly important as they provide specificity by recognizing particular target proteins. Different classes of E3 ligases—RING, HECT, and RBR—each have unique mechanisms for transferring ubiquitin to their targets 1 3 .
E1 enzyme activates ubiquitin using ATP, forming a thioester bond
E2 enzyme carries activated ubiquitin to the target protein
E3 ligase facilitates transfer of ubiquitin to the target protein
Ubiquitinated protein is recognized by the 19S regulatory particle
Protein is unfolded and degraded within the 20S core particle
Once a protein is appropriately tagged, the regulatory particle unfolds it and feeds it into the core's central chamber, where the proteolytic active sites break it down into small peptide fragments. This process, known as the ubiquitin-proteasome system (UPS), is crucial for maintaining cellular homeostasis by regulating the levels of key proteins involved in cell cycle progression, DNA repair, and—most importantly for cancer therapy—programmed cell death or apoptosis .
Cancer cells are characterized by rapid, uncontrolled division, which generates significant protein waste and metabolic stress. To manage this burden and maintain survival, cancer cells upregulate proteasome subunits and activity compared to normal cells 5 . This heightened dependency on the proteasome creates a therapeutic Achilles' heel—by inhibiting the proteasome, we can push these already-stressed cells over the edge into self-destruction.
The connection between proteasomes and cancer extends beyond mere protein cleanup. The UPS precisely controls the levels of key regulatory proteins, including the B-cell lymphoma-2 (Bcl-2) family of proteins that govern the mitochondrial pathway of apoptosis 1 3 . In many cancers, anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1 are overexpressed, creating a powerful shield against cell death. Meanwhile, pro-apoptotic proteins like Bax, Bak, and various BH3-only proteins are often downregulated or degraded. This imbalance allows cancer cells to evade the natural cell death that would normally eliminate them 1 .
| Protein | Type | Role in Cancer | Associated Cancers |
|---|---|---|---|
| Bcl-2 | Anti-apoptotic | Frequently overexpressed, promotes cell survival | Breast, gastric, hematological, lung, prostate |
| Mcl-1 | Anti-apoptotic | Promotes cell survival, often implicated in drug resistance | Gynecologic, lung, melanoma |
| Bim | Pro-apoptotic | Initiates cell death, often degraded in cancer | Oral cancer |
| Noxa | Pro-apoptotic | Initiates cell death, regulated by proteasome | Breast, colorectal, leukemia, lung, melanoma, myeloma |
| Bax | Pro-apoptotic | Executioner of cell death, often inactivated | Breast, gastric, liver |
Table 1: Key Bcl-2 Family Proteins Regulated by the Proteasome in Cancer
A pivotal study published in Cell Death & Disease in 2025 investigated whether proteasome inhibition could overcome resistance to targeted therapies in B-cell malignancies 8 . Researchers faced a critical clinical problem: patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who developed resistance to PI3K inhibitors like idelalisib had limited treatment options, creating an urgent need for alternative approaches.
The research team developed two idelalisib-resistant B-cell cancer models—KARPAS1718 and VL51—by continuously exposing the parental cell lines to the drug. They then subjected these resistant models, along with primary CLL cells from treatment-naive and idelalisib-resistant patients, to comprehensive drug sensitivity screening.
The study revealed strikingly different resistance patterns between the two models. While idelalisib-resistant KARPAS1718 cells remained sensitive to Bcl-2 inhibitors, the resistant VL51 line showed significantly reduced sensitivity to these agents. This difference correlated with variations in Bcl-2 family member phosphorylation and expression patterns 8 .
| Cell Model | Sensitivity to Proteasome Inhibitor |
|---|---|
| KARPAS1718 (Parental) | Sensitive |
| KARPAS1718 (Idelalisib-Resistant) | Sensitive |
| VL51 (Parental) | Sensitive |
| VL51 (Idelalisib-Resistant) | Sensitive |
| Primary CLL (Treatment-Naive) | Sensitive |
| Primary CLL (Idelalisib-Resistant) | Sensitive |
Table 2: Proteasome Inhibitor Efficacy Across Different Cell Models
At the molecular level, proteasome inhibitor treatment consistently upregulated the pro-apoptotic protein Bim and altered the balance of anti-apoptotic proteins Mcl-1 and Bcl-2. When combined with Bcl-2 inhibitors, proteasome inhibitors produced an additive effect, suggesting potential for combination therapies 8 .
The clinical relevance of these findings was demonstrated in a multi-refractory CLL patient treated with a combination of Bcl-2 and proteasome inhibitors. The patient experienced initial clinical improvement with significantly better quality of life, though relapse occurred within four months. Analysis of patient samples during treatment mirrored the laboratory findings—upregulation of Bim and Mcl-1, along with reductions in cytotoxic immune cells 8 .
Research into proteasomal subunits and their therapeutic applications relies on a sophisticated array of reagents and tools.
Block proteasome activity to induce cancer cell death; used both as therapeutics and research tools
Measure drug effectiveness and cancer cell killing
Identifies signaling pathway changes in response to treatment
Measures changes in proteasome subunit genes and their relationship to cancer outcomes
| Reagent/Tool | Function/Application | Example from Research |
|---|---|---|
| Proteasome Inhibitors | Block proteasome activity to induce cancer cell death; used both as therapeutics and research tools | Ixazomib, Bortezomib 8 |
| Cell Viability Assays | Measure drug effectiveness and cancer cell killing | CellTiter-Glo luminescent assay 8 |
| Phosphoprotein Profiling | Identifies signaling pathway changes in response to treatment | Fluorescent cell barcoding 8 |
| Gene Expression Analysis | Measures changes in proteasome subunit genes and their relationship to cancer outcomes | TCGA data analysis, DNA methylation studies 4 |
| Animal Disease Models | Tests therapeutic efficacy and toxicity in living organisms | PS19 mice (for tau pathology) 2 |
| Cryo-Electron Microscopy | Determines high-resolution structures of proteasomal complexes | Midnolin-proteasome structure determination 9 |
| Assembly Chaperones | Regulates proteasome formation and function | S5b/PSMD5 manipulation 2 |
| Ubiquitin System Components | Controls target specificity for degradation | E1, E2, E3 ubiquitin ligases 1 |
Table 4: Essential Research Reagents in Proteasome Studies
While current proteasome inhibitors have shown significant clinical success, particularly in multiple myeloma and other blood cancers, they face limitations including side effects and developing resistance 9 . Next-generation strategies are focusing on more precise targeting approaches:
Research has revealed that higher levels of specialized immunoproteasomes are linked to better immunotherapy outcomes in melanoma patients 6 . These specialized proteasomes, which contain alternative catalytic subunits, are particularly important in immune cells for generating antigen fragments that are displayed to T-cells.
Targeting immunoproteasome-specific subunits could potentially enhance anti-tumor immune responses while reducing side effects associated with broad proteasome inhibition.
Recent structural work using cryo-electron microscopy has revealed the structure of midnolin, a protein that helps ferry other proteins to proteasomes for degradation without requiring the typical ubiquitin tag 9 . This "ubiquitin-independent" pathway represents a new frontier in proteasome research.
Since midnolin appears to be particularly important for the survival of malignant B-cells but is found primarily in these cells, targeting it could offer a safer alternative to broad proteasome inhibitors that affect all cell types.
Rather than directly inhibiting proteasome activity, some researchers are exploring ways to manipulate proteasome assembly. A 2025 study found that reducing levels of the S5b/PSMD5 protein increased formation of 26S and 30S proteasomes, which enhanced degradation of aggregation-prone proteins and improved cognitive function in a mouse model of tauopathy 2 .
While this approach was studied in neurodegenerative disease, it suggests potential strategies for manipulating proteasome composition and function in cancer cells specifically.
Current research focuses on developing more specific, targeted approaches to proteasome modulation with fewer side effects.
The proteasome represents a remarkable example of how understanding fundamental cellular machinery can lead to innovative cancer therapies. From the first proteasome inhibitors to the emerging strategies targeting specific subunits and associated proteins, this field continues to evolve rapidly. The research highlighted in this article demonstrates that targeting the proteasome can overcome resistance to other therapies, offering hope for patients with limited options.
The ongoing research into the proteasome's intricate structure and regulation continues to reveal new therapeutic possibilities, making it one of the most exciting frontiers in the ongoing battle against cancer. With continued investigation and clinical translation, proteasome-targeted therapies are poised to become an increasingly important pillar of cancer treatment in the years to come.
Multiple FDA-approved proteasome inhibitors
Novel targets and combination strategies
Precision targeting with fewer side effects
References will be added here manually in the required format.